Improving Lives Through
Innovative Diagnostic Solutions
AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests.
Improving Lives Through
Innovative Diagnostic Solutions
AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests.
oncological
solutions
AXIM Biotech is in development of a rapid (10-minute) diagnostic test that detects active biomarkers for early detection of cancer
OPHTHALMOLOGICAL DIAGNOSTICS
AXIM has developed and commercialized two point-of-care ophthalmological diagnostic solutions focused on diagnosis of Dry Eye Disease (DED)
DIAGNOSTIC
TEST DEVELOPMENT
Through AXIM’s vertically integrated research and development platform, AXIM is capable of developing diagnostic solutions for a variety of conditions – based on the needs of the client
oncological
solutions
AXIM Biotech is in development of a rapid (10-minute) diagnostic test that detects active biomarkers for early detection of cancer
OPHTHALMOLOGICAL DIAGNOSTICS
AXIM has developed and commercialized two point-of-care ophthalmological diagnostic solutions focused on diagnosis of Dry Eye Disease (DED)
DIAGNOSTIC
TEST DEVELOPMENT
Through AXIM’s vertically integrated research and development platform, AXIM is capable of developing diagnostic solutions for a variety of conditions – based on the needs of the client
About AXIM
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease.
AXIM® Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing
Leading Diagnostic Healthcare Company Announces Provisional Patent Filing on Proprietary Use of Materials for Ophthalmological Test Strip Manufacturing SAN DIEGO, TBD DATE, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or...
AXIM® Biotechnologies Files Patent on Fentanyl Neutralizing Antibody Test, Applies for DEA License to Work With Controlled Substance
Diagnostic Healthcare Solutions Company Developing New Test Designed to Measure Neutralizing Antibodies of Deadly Opioid Fentanyl SAN DIEGO, TBD DATE, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...
AXIM Biotechnologies CEO Issues Letter to Shareholders
Summary: In 2022, AXIM® finalized optimization of its R&D and manufacturing infrastructure to be used in its diagnostic program AXIM will continue to generate revenue from its two FDA-cleared dry eye disease (DED) diagnostic tests through commercialization partner...